SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE

• 收藏
• 分享

专利权人:

Santaris Pharma A/S;Ercole Biotech, Inc.

发明人:

Ørum, Henrik,Sazani, Peter L.

申请号：

AU2019208249

公开号：

AU2019208249A1

申请日:

2019.07.26

申请国别(地区):

AU

年份:

2019

代理人:

摘要：

#$%^&*AU2019208249A120190815.pdf#####ABSTRACT The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has therapeutic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/